Nektar's bitter pill: Phase 2 fail ends Lilly-partnered lupus program— Jounce slashes 57% of staff, drops assets in stock merger with Redx —GSK's ViiV says study shows its long-acting HIV shot as effective as Gilead's daily pill-- See more on our front page news http://bit.ly/w28kSd #nektartherapeutics #clinicaltrials #elililly #lupus #layoffs #reversemerger #hiv #gsk #gileadsciences #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#nektartherapeutics #clinicaltrials #elililly #lupus #layoffs #reversemerger #hiv #gsk #gileadsciences #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma